vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Shake Shack Inc. (SHAK). Click either name above to swap in a different company.

Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $366.7M, roughly 2.0× Shake Shack Inc.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs -0.1%, a 10.9% gap on every dollar of revenue. On growth, Shake Shack Inc. posted the faster year-over-year revenue change (14.3% vs 3.9%). Over the past eight quarters, Shake Shack Inc.'s revenue compounded faster (7.6% CAGR vs 1.5%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

Shake Shack is an American multinational fast casual restaurant chain based in New York City. It started out as a hot dog cart inside Madison Square Park in 2001, and its popularity steadily grew. In 2004, it received a permit to open a permanent kiosk within the park, expanding its menu from New York–style hot dogs to one with hamburgers, hot dogs, fries and its namesake milkshakes.

AMRX vs SHAK — Head-to-Head

Bigger by revenue
AMRX
AMRX
2.0× larger
AMRX
$722.5M
$366.7M
SHAK
Growing faster (revenue YoY)
SHAK
SHAK
+10.4% gap
SHAK
14.3%
3.9%
AMRX
Higher net margin
AMRX
AMRX
10.9% more per $
AMRX
10.8%
-0.1%
SHAK
Faster 2-yr revenue CAGR
SHAK
SHAK
Annualised
SHAK
7.6%
1.5%
AMRX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
AMRX
AMRX
SHAK
SHAK
Revenue
$722.5M
$366.7M
Net Profit
$78.0M
$-294.0K
Gross Margin
44.3%
Operating Margin
19.6%
Net Margin
10.8%
-0.1%
Revenue YoY
3.9%
14.3%
Net Profit YoY
410.5%
EPS (diluted)
$0.19
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
SHAK
SHAK
Q1 26
$722.5M
$366.7M
Q4 25
$814.3M
$400.5M
Q3 25
$784.5M
$367.4M
Q2 25
$724.5M
$356.5M
Q1 25
$695.4M
$320.9M
Q4 24
$730.5M
$328.7M
Q3 24
$702.5M
$316.9M
Q2 24
$701.8M
$316.5M
Net Profit
AMRX
AMRX
SHAK
SHAK
Q1 26
$78.0M
$-294.0K
Q4 25
$35.1M
$11.8M
Q3 25
$2.4M
$12.5M
Q2 25
$22.4M
$17.1M
Q1 25
$12.2M
$4.2M
Q4 24
$-31.1M
$8.7M
Q3 24
$-156.0K
$-10.2M
Q2 24
$6.0M
$9.7M
Gross Margin
AMRX
AMRX
SHAK
SHAK
Q1 26
44.3%
Q4 25
36.5%
Q3 25
34.9%
Q2 25
39.5%
Q1 25
36.8%
Q4 24
36.0%
Q3 24
38.4%
Q2 24
35.6%
Operating Margin
AMRX
AMRX
SHAK
SHAK
Q1 26
19.6%
Q4 25
13.8%
4.7%
Q3 25
9.0%
5.0%
Q2 25
15.4%
6.3%
Q1 25
14.4%
0.9%
Q4 24
10.4%
3.1%
Q3 24
12.6%
-5.7%
Q2 24
13.6%
3.4%
Net Margin
AMRX
AMRX
SHAK
SHAK
Q1 26
10.8%
-0.1%
Q4 25
4.3%
3.0%
Q3 25
0.3%
3.4%
Q2 25
3.1%
4.8%
Q1 25
1.8%
1.3%
Q4 24
-4.3%
2.6%
Q3 24
-0.0%
-3.2%
Q2 24
0.9%
3.1%
EPS (diluted)
AMRX
AMRX
SHAK
SHAK
Q1 26
$0.19
$-0.01
Q4 25
$0.10
$0.28
Q3 25
$0.01
$0.30
Q2 25
$0.07
$0.41
Q1 25
$0.04
$0.10
Q4 24
$-0.10
$0.22
Q3 24
$0.00
$-0.26
Q2 24
$0.02
$0.23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
SHAK
SHAK
Cash + ST InvestmentsLiquidity on hand
$197.7M
$313.6M
Total DebtLower is stronger
$248.0M
Stockholders' EquityBook value
$554.6M
Total Assets
$3.5B
$1.9B
Debt / EquityLower = less leverage
0.45×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
SHAK
SHAK
Q1 26
$197.7M
$313.6M
Q4 25
$282.0M
$360.1M
Q3 25
$201.2M
$357.8M
Q2 25
$71.5M
$336.8M
Q1 25
$59.2M
$312.9M
Q4 24
$110.6M
$320.7M
Q3 24
$74.0M
$310.9M
Q2 24
$43.8M
$304.4M
Total Debt
AMRX
AMRX
SHAK
SHAK
Q1 26
$248.0M
Q4 25
$2.6B
$247.7M
Q3 25
$2.6B
$247.5M
Q2 25
$2.2B
$247.2M
Q1 25
$2.2B
$246.9M
Q4 24
$2.4B
$246.7M
Q3 24
$2.4B
$246.4M
Q2 24
$2.4B
$246.2M
Stockholders' Equity
AMRX
AMRX
SHAK
SHAK
Q1 26
$554.6M
Q4 25
$-70.8M
$525.3M
Q3 25
$-109.5M
$509.0M
Q2 25
$-112.1M
$494.1M
Q1 25
$-131.7M
$473.3M
Q4 24
$-109.3M
$470.0M
Q3 24
$-93.4M
$456.1M
Q2 24
$-57.5M
$462.4M
Total Assets
AMRX
AMRX
SHAK
SHAK
Q1 26
$3.5B
$1.9B
Q4 25
$3.7B
$1.9B
Q3 25
$3.6B
$1.8B
Q2 25
$3.4B
$1.8B
Q1 25
$3.4B
$1.7B
Q4 24
$3.5B
$1.7B
Q3 24
$3.5B
$1.7B
Q2 24
$3.5B
$1.7B
Debt / Equity
AMRX
AMRX
SHAK
SHAK
Q1 26
0.45×
Q4 25
0.47×
Q3 25
0.49×
Q2 25
0.50×
Q1 25
0.52×
Q4 24
0.52×
Q3 24
0.54×
Q2 24
0.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
SHAK
SHAK
Operating Cash FlowLast quarter
$8.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
SHAK
SHAK
Q1 26
$8.5M
Q4 25
$130.3M
$63.1M
Q3 25
$118.5M
$63.0M
Q2 25
$83.8M
$65.0M
Q1 25
$7.4M
$31.2M
Q4 24
$118.1M
$45.1M
Q3 24
$141.8M
$41.9M
Q2 24
$39.7M
$53.5M
Free Cash Flow
AMRX
AMRX
SHAK
SHAK
Q1 26
Q4 25
$108.5M
$4.0M
Q3 25
$106.2M
$23.7M
Q2 25
$61.0M
$26.9M
Q1 25
$-5.8M
$1.9M
Q4 24
$102.9M
$10.4M
Q3 24
$124.8M
$7.1M
Q2 24
$29.0M
$20.6M
FCF Margin
AMRX
AMRX
SHAK
SHAK
Q1 26
Q4 25
13.3%
1.0%
Q3 25
13.5%
6.5%
Q2 25
8.4%
7.5%
Q1 25
-0.8%
0.6%
Q4 24
14.1%
3.2%
Q3 24
17.8%
2.2%
Q2 24
4.1%
6.5%
Capex Intensity
AMRX
AMRX
SHAK
SHAK
Q1 26
Q4 25
2.7%
14.8%
Q3 25
1.6%
10.7%
Q2 25
3.2%
10.7%
Q1 25
1.9%
9.1%
Q4 24
2.1%
10.6%
Q3 24
2.4%
11.0%
Q2 24
1.5%
10.4%
Cash Conversion
AMRX
AMRX
SHAK
SHAK
Q1 26
Q4 25
3.72×
5.34×
Q3 25
50.00×
5.04×
Q2 25
3.74×
3.79×
Q1 25
0.61×
7.36×
Q4 24
5.18×
Q3 24
Q2 24
6.62×
5.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons